ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical efficacy and safety of angong niuhuang pill (ANP) as an adjuvant treatment on moderate or severe neonatal hypoxic-ischemic encephalopathy (NHIE).</p><p><b>METHODS</b>Thirty-nine neonates with NHIE in the control group were treated with conventional treatment, and 58 in the treated group were administered orally ANP additionally, and relative indexes were observed.</p><p><b>RESULTS</b>The improvement of aspects such as recovery of consciousness, muscular tension, and primitive reflex and disappearance of convulsion, in the treated group was better than that in the control group (P < 0.01).</p><p><b>CONCLUSION</b>ANP as an adjuvant treatment has a definite effect on NHIE, it can promote the recovery of patients, decrease the occurrence of sequelae and with high safety, therefore, is a drug feasible for clinical application.</p>
Subject(s)
Female , Humans , Infant, Newborn , Male , Asphyxia Neonatorum , Drug Therapy , Drug Therapy, Combination , Drugs, Chinese Herbal , Therapeutic Uses , Hypoxia-Ischemia, Brain , Drug Therapy , PhytotherapyABSTRACT
Objective:To evaluate the application of analyzing neutrophil cell surface marker CD64 in diagnosis of premature infants infection.Methods:109 infants inpatient in neonatal department(including NICU)were enrolled in the study.CD64 was measured by FCM,which was compared with C-reactive protein(CRP)and IL-6.Results:There was a statistically significant difference in quantitation of CD64 on neutrophil cells(P